Thus, this pathway may constitute a valid alternative for the treatment of conditions characterized by impairments in vasopressin signaling or vasopressin type 2 receptor (AVPR2) expression, such as NDI, polycystic kidney disease (PKD), or the syndrome of inappropriate secretion of AVP (SIADH). This evidence concerns the gene AVPR2 and inappropriate ADH syndrome.